High volume has been associated with better outcomes across different areas of medicine.1 As thyroid specialists, Thyroid Cytopathology Partners (TCP) brings the kind of experience only gained from a high volume of cases, allowing clear and confident diagnoses.
In fact, TCP has a total thyroid cytopathology volume >5,000 cases/month.2
*Indeterminate (Bethesda III/IV) includes atypia of undermined significance or follicular lesion of undermined significance (AUS/FLUS) and follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN).
1. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137:511-520.
2. Data on file at Thyroid Cytopathology Partners. August 2018.
3. Sermo market research study of pathologists who perform cytology on thyroid FNAs. April 2013.
4. Houlton JJ, Sun GH, Fernandez N, Zhai QJ, Lucas F, Steward DL. Thyroid fine-needle aspiration: does case volume affect diagnostic yield and interpretation? Arch Otolaryngol Head Neck Surg. 2011;137:1136-1139.
5. Olson MT, Boonyaarunnate T, Han PA, et al. A tertiary center’s experience with second review of 3885 thyroid cytopathology specimens. J Clin Endocrinol Metab. 2013;98:1450-1457.
6. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009;19:1159-1165.
7. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.